- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Disparities in Germline Genetic Testing Rates Exist, but Mechanisms Remain Unclear
Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, discussed the importance of germline genetic testing in patients with triple-negative breast cancer and other cancer types.
Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, discussed the importance of germline genetic testing in patients with triple-negative breast cancer and other cancer types.
In a study presented at the 2023 American Society of Clinical Oncology Annual Meeting, Kunz and colleagues found that social determinants of health, particularly related to race and the type of insurance coverage patients had, impacted genetic testing rates in the community oncology setting.
Transcript
What are the implications of these findings for patients with TNBC and other cancer types where germline testing is recommended?
I think the biggest implication is trying to understand why these differences exist, and how can we address them? And where along the whole genetic testing workflow these people weren't getting what they needed. Were they not identified in the first place for genetic testing? Were they not referred, were they referred and didn't have an appointment? If they had an appointment, why did they choose not to do testing?
And it's not that everyone should do testing—people have options and real reasons why they don't do testing. But we need to understand why there's that discrepancy and address it. And it will apply to other cancers. Can we do systemic things like change workflows to make sure that people don't overlook these indications for genetic testing? Because the indications for genetic testing are just going to keep increasing, and we need our providers really understand that, and our patients [need to] understand the value of genetic testing.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Study Highlights Disparities in Access to In-Network Mental Health Care vs Medical Care
April 17th 2024While health plans often employ reimbursement rates as a tool to incentivize provider participation within their networks, study results showed reimbursement rates for office visits with medical/surgical clinicians were on average 22% higher than behavioral health clinicians.
Read More
